S A Montgomery

Summary

Affiliation: Imperial College School of Medicine
Country: UK

Publications

  1. doi request reprint Efficacy of escitalopram compared to citalopram: a meta-analysis
    Stuart Montgomery
    University of London, UK
    Int J Neuropsychopharmacol 14:261-8. 2011
  2. ncbi request reprint Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
    Stuart A Montgomery
    Imperial College School of Medicine, PO Box 8751, London, UK
    J Psychiatr Res 36:209-17. 2002
  3. ncbi request reprint Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    J Clin Psychiatry 67:771-82. 2006
  4. doi request reprint Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder
    Stuart A Montgomery
    Imperial College School of Medicine, London, England, UK
    Int Clin Psychopharmacol 24:296-305. 2009
  5. doi request reprint Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, London, United Kingdom
    J Clin Psychiatry 74:363-9. 2013
  6. ncbi request reprint Antidepressants and seizures: emphasis on newer agents and clinical implications
    S A Montgomery
    Imperial College of Medicine, University of London, UK
    Int J Clin Pract 59:1435-40. 2005
  7. ncbi request reprint Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders
    Stuart A Montgomery
    Imperial College, University of London, UK
    Int Clin Psychopharmacol 17:S9-15; discussion S16-7. 2002
  8. ncbi request reprint Which antidepressants have demonstrated superior efficacy? A review of the evidence
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, UK
    Int Clin Psychopharmacol 22:323-9. 2007
  9. ncbi request reprint ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder
    S A Montgomery
    Eur Neuropsychopharmacol 14:425-33. 2004
  10. ncbi request reprint Pregabalin for the treatment of generalised anxiety disorder
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, PO Box 8751, W13 8WH, UK
    Expert Opin Pharmacother 7:2139-54. 2006

Detail Information

Publications46

  1. doi request reprint Efficacy of escitalopram compared to citalopram: a meta-analysis
    Stuart Montgomery
    University of London, UK
    Int J Neuropsychopharmacol 14:261-8. 2011
    ..0003) for response and 1.86 (p<0.0001) for remission, in favour of escitalopram. In this meta-analysis, the statistically significant superior efficacy of escitalopram compared to citalopram was shown to be clinically relevant...
  2. ncbi request reprint Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
    Stuart A Montgomery
    Imperial College School of Medicine, PO Box 8751, London, UK
    J Psychiatr Res 36:209-17. 2002
    ..To characterize the response to the serotonin and norepinephrine reuptake inhibitor, venlafaxine extended release (XR), during the long-term treatment of generalized anxiety disorder...
  3. ncbi request reprint Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    J Clin Psychiatry 67:771-82. 2006
    ..The current study compared the efficacy and safety of pregabalin and venlafaxine in patients diagnosed with moderate to severe GAD...
  4. doi request reprint Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder
    Stuart A Montgomery
    Imperial College School of Medicine, London, England, UK
    Int Clin Psychopharmacol 24:296-305. 2009
    ..029). In conclusion, cessation of desvenlafaxine use is associated with discontinuation symptoms after both short-term and long-term treatment...
  5. doi request reprint Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, London, United Kingdom
    J Clin Psychiatry 74:363-9. 2013
    ..To investigate the efficacy and safety of levomilnacipran sustained release (SR), an antidepressant candidate in late-stage development, in major depressive disorder (MDD)...
  6. ncbi request reprint Antidepressants and seizures: emphasis on newer agents and clinical implications
    S A Montgomery
    Imperial College of Medicine, University of London, UK
    Int J Clin Pract 59:1435-40. 2005
    ..Seizure risk, along with other drug-related considerations, e.g. weight gain, sexual dysfunction and sedation, should be considered when prescribing an antidepressant...
  7. ncbi request reprint Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders
    Stuart A Montgomery
    Imperial College, University of London, UK
    Int Clin Psychopharmacol 17:S9-15; discussion S16-7. 2002
    ..The body of studies supports the view that amisulpride is an effective and well-tolerated treatment for dysthymia and dysthymia with major depression...
  8. ncbi request reprint Which antidepressants have demonstrated superior efficacy? A review of the evidence
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, UK
    Int Clin Psychopharmacol 22:323-9. 2007
    ..This review of published data found evidence that only a very few antidepressants are shown to be more effective than others...
  9. ncbi request reprint ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder
    S A Montgomery
    Eur Neuropsychopharmacol 14:425-33. 2004
  10. ncbi request reprint Pregabalin for the treatment of generalised anxiety disorder
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, PO Box 8751, W13 8WH, UK
    Expert Opin Pharmacother 7:2139-54. 2006
    ..The discontinuation symptoms following abrupt treatment cessation were similar to the rates with serotonin-noradrenaline re-uptake inhibitors and lower than with benzodiazepines with no signals of tolerance or dependence...
  11. ncbi request reprint Venlafaxine versus placebo in the preventive treatment of recurrent major depression
    Stuart A Montgomery
    Imperial College School of Medicine, PO Box 8751, London W13 8WH, England, UK
    J Clin Psychiatry 65:328-36. 2004
    ..Long-term efficacy and safety of prophylactic venlafaxine treatment were evaluated in outpatients with recurrent major depression...
  12. ncbi request reprint A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder
    S A Montgomery
    Imperial College School of Medicine, London, UK
    Neuropsychobiology 50:57-64. 2004
    ..01). Thus escitalopram treatment was similar to venlafaxine treatment with respect to efficacy and was better tolerated by patients in primary care...
  13. ncbi request reprint Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study
    S A Montgomery
    Imperial College University of London, London, UK
    Int Clin Psychopharmacol 19:271-80. 2004
    ..001). No significant difference was shown between the continuing and interrupting groups in the second week of discontinuation. By contrast to paroxetine, abrupt cessation of agomelatine is not associated with discontinuation symptoms...
  14. ncbi request reprint Escitalopram versus venlafaxine XR in the treatment of depression
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, London, UK
    Int Clin Psychopharmacol 21:297-309. 2006
    ..2% in the venlafaxine XR group. The mean number of discontinuation emergent signs and symptoms in the venlafaxine XR group (mean: 5.0) was significantly (P<0.001) higher than for the escitalopram group (mean: 2.4)...
  15. ncbi request reprint A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder
    Stuart A Montgomery
    Imperial College, London, UK
    J Clin Psychiatry 66:1270-8. 2005
    ..The present relapse prevention study investigated relapse rates during a 24-week, randomized, double-blind, placebo-controlled period in patients with generalized SAD who had responded to 12-week open-label treatment with escitalopram...
  16. ncbi request reprint Why do we need new and better antidepressants?
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, UK
    Int Clin Psychopharmacol 21:S1-S10. 2006
    ....
  17. ncbi request reprint Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease
    Stuart A Montgomery
    Imperial College University of London, London, UK
    Int Clin Psychopharmacol 18:61-71. 2003
    ..The beneficial effects were seen on both the clinical scales and the psychometric tests. The advantage for Alcar was seen by the time of the first assessment at 3 months and increased over time. Alcar was well tolerated in all studies...
  18. ncbi request reprint The antidepressant efficacy of reboxetine in patients with severe depression
    Stuart Montgomery
    Imperial College School of Medicine, London, U K
    J Clin Psychopharmacol 23:45-50. 2003
    ..These results demonstrate that reboxetine is significantly more effective than placebo in a subgroup of patients with severe depression...
  19. ncbi request reprint Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, London, United Kingdom
    CNS Spectr 13:27-33. 2008
    ..This problem appears to be unique to duloxetine and not a characteristic of the SNRI class. There are differences in overdose toxicity between venlafaxine and the other SNRIs, possibly related to its increased cardiotoxicity...
  20. ncbi request reprint Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, London, UK
    Int Clin Psychopharmacol 22:283-91. 2007
    ..06 rising to 4.45 points on the Hamilton Depression Rating Scale. In conclusion, agomelatine is effective in treating severe depression...
  21. ncbi request reprint Selecting methodologies for the evaluation of differences in time to response between antidepressants
    Stuart A Montgomery
    Imperial College School of Medicine, London, United Kingdom
    J Clin Psychiatry 63:694-9. 2002
    ..The delay in the therapeutic effect of antidepressants is a considerable impediment to their successful clinical use, and attention has recently been focused on antidepressant drugs that may have a faster onset of action...
  22. doi request reprint Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, London bLudwig Maximilians University, Munich, UK
    Int Clin Psychopharmacol 24:111-8. 2009
    ..Both of these measures demonstrate a clinically relevant difference in favour of escitalopram...
  23. doi request reprint Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder
    Stuart Montgomery
    PO Box 8751, London W13 8WH, UK
    Br J Psychiatry 193:389-94. 2008
    ..Pregabalin is a novel compound that has been shown to have efficacy in the treatment of generalised anxiety disorder and is licensed for the treatment of the disorder in the European Union...
  24. doi request reprint The under-recognized role of dopamine in the treatment of major depressive disorder
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    Int Clin Psychopharmacol 23:63-9. 2008
    ..The potential role of atypical antipsychotics such as olanzapine, risperidone and quetiapine in the treatment of MDD is explored based on evidence from bipolar depression trials and preliminary studies in patients with MDD...
  25. ncbi request reprint Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction
    S A Montgomery
    Department of Pharmacology, Imperial College School of Medicine, P O Box 8751, London W13 8WH, UK
    J Affect Disord 69:119-40. 2002
    ..However, there is little detailed information on the prevalence of drug-induced sexual dysfunction or the differences, if any, between available drugs. This article is a critical review of the literature in the area...
  26. ncbi request reprint Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder
    S A Montgomery
    Imperial College of Science, Technology and Medicine, London, UK
    Int Clin Psychopharmacol 16:75-86. 2001
    ..05 on citalopram 60 mg and 20 mg versus placebo for the social life and home activities). Citalopram was well tolerated; only 4 to 6 patients in each dose group discontinued the study prematurely due to adverse events...
  27. ncbi request reprint Social phobia: diagnosis, severity and implications for treatment
    S A Montgomery
    Department of Pharmacology, Imperial College School of Medicine at St Mary's, London, UK
    Eur Arch Psychiatry Clin Neurosci 249:S1-6. 1999
    ..The introduction of these treatments should encourage people with social phobia to seek medical help for this hitherto much neglected disorder...
  28. ncbi request reprint Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts
    D B Montgomery
    Department of Psychiatry, St Mary's Hospital Medical School, London, England
    Eur Arch Psychiatry Clin Neurosci 244:211-5. 1994
    ..Since fluoxetine is clearly effective with recurrent major depression, it would appear that recurrent brief depression has a different pharmacology...
  29. ncbi request reprint A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression
    S A Montgomery
    Imperial College School of Medicine, London, UK
    Int Clin Psychopharmacol 16:169-78. 2001
    ....
  30. ncbi request reprint Plasma-level response relationships with fluoxetine and zimelidine
    S A Montgomery
    Academic Department of Psychiatry, Medical School, St Mary s Hospital, London, England
    Clin Neuropharmacol 13:S71-5. 1990
    ..Fixed-dose pharmacokinetic studies are recommended as part of the program to establish the best dose of new antidepressants...
  31. ncbi request reprint ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004
    S A Montgomery
    Eur Neuropsychopharmacol 17:70-7. 2007
  32. ncbi request reprint Why do amitriptyline and dothiepin appear to be so dangerous in overdose?
    S A Montgomery
    St Mary s Hospital Medical School, London, United Kingdom
    Acta Psychiatr Scand Suppl 354:47-53. 1989
    ..4. There may be a selective overreporting of deaths with amitriptyline and dothiepin. 5. Amitriptyline and prothiaden may be selectively given to the suicide prone on the mistaken assumption that they are safe...
  33. ncbi request reprint Suicide and antidepressants
    S A Montgomery
    Imperial College of Medicine, St Mary s London, United Kingdom
    Ann N Y Acad Sci 836:329-38. 1997
    ..Toxic antidepressants should be avoided in those thought to be at particular risk...
  34. ncbi request reprint Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder
    Jose Luis Fernandez
    London School of Economics, London, United Kingdom
    Pharmacoeconomics 23:155-67. 2005
    ..To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major depressive disorder (MDD)...
  35. ncbi request reprint Partial response and nonresponse to antidepressant therapy: current approaches and treatment options
    Robert M A Hirschfeld
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston 77555 0188, USA
    J Clin Psychiatry 63:826-37. 2002
    ..Switching to an agent of a different class is probably optimal for those patients who fail to respond to first-line therapy...
  36. ncbi request reprint Late-life depression: rationalizing pharmacological treatment options
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    Gerontology 48:392-400. 2002
    ..There is little doubt that effective and well-tolerated antidepressant therapy is required...
  37. ncbi request reprint WCA recommendations for the long-term treatment of social phobia
    Michael Van Ameringen
    Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    CNS Spectr 8:40-52. 2003
    ..In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months...
  38. doi request reprint A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder
    Daniel Z Lieberman
    George Washington University Clinical Psychiatric Research Center, Washington, DC 20037, USA
    Int Clin Psychopharmacol 23:188-97. 2008
    ..001)]. Adverse events were comparable to those found with other drugs sharing a similar mechanism of action. These data support the efficacy, safety, and tolerability of desvenlafaxine in the treatment of major depressive disorder...
  39. ncbi request reprint Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis
    Stuart A Montgomery
    Imperial College School of Medicine, London, United Kingdom
    J Clin Psychopharmacol 22:561-7. 2002
    ..Overall, these results demonstrate the clinical effectiveness of venlafaxine XR in the short-term and long-term treatment of GAD...
  40. ncbi request reprint Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:1907-12. 2007
    ..The current analysis was undertaken to determine if these antidepressants differ in rapidity of clinical effect...
  41. ncbi request reprint Improving the chance of recovery from the short- and long-term consequences of depression
    Hans Jurgen Moller
    Ludwig Maximilians University, Department of Psychiatry, Munich, Germany
    Int Clin Psychopharmacol 18:219-25. 2003
    ..In conclusion, there remains considerable scope for improving the identification, treatment and management of patients with MDD...
  42. ncbi request reprint WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults
    John H Greist
    Healthcare Technology Systems, Inc, Madison, Wisconsin 53717, USA
    CNS Spectr 8:7-16. 2003
    ..Further, pharmacotherapy for a minimum of 1-2 years is recommended before very gradual withdrawal may be considered...
  43. ncbi request reprint WCA recommendations for the long-term treatment of generalized anxiety disorder
    Christer Allgulander
    Department of Psychiatry, Harvard University School of Medicine, Boston, Massachusetts, USA
    CNS Spectr 8:53-61. 2003
    ..Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD...
  44. ncbi request reprint Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study
    David G Perahia
    Lilly Research Centre, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    Br J Psychiatry 188:346-53. 2006
    ..Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission...
  45. ncbi request reprint Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder
    Stuart A Montgomery
    Imperial College School of Medicine, London, UK
    Int J Neuropsychopharmacol 9:517-28. 2006
    ..Nemifitide showed a good tolerability and safety profile. There were no dropouts due to adverse events, and the incidence of side-effects with nemifitide was comparable with that of placebo...
  46. ncbi request reprint Discontinuation symptoms in depression and anxiety disorders
    David S Baldwin
    Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 10:73-84. 2007
    ..Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment...